Certara, DMTC study preventative use of chloroquine for COVID-19

By The Science Advisory Board staff writers

May 7, 2020 -- Certara and DMTC have entered into a research collaboration to evaluate the preventative use of chloroquine in healthcare workers at risk of infection from SARS-CoV-2, the coronavirus strain responsible for COVID-19.

The randomized controlled trial will be led by DMTC, formerly the Defence Materials Technology Centre. The trial will develop mathematical models to understand the viral time course and factors affecting drug exposure and prophylactic response in healthy adult healthcare workers at risk of SARS-CoV-2 infection.

In the study, participants will receive a loading dose followed by weekly doses of chloroquine or placebo to be assessed over a 14-week period.

Certara will provide clinical pharmacology expertise by analyzing the data and conducting exposure-response research to build the model.

Scripps Research expands drug repurposing efforts for COVID-19
Scripps Research has pivoted its drug repurposing collection ReFRAME to find antiviral compounds effective against the novel coronavirus.
Controversy hits Gilead over orphan status for COVID-19 drug
Gilead Sciences has rescinded its request for orphan drug status for an experimental drug for treating COVID-19 just two days after getting approval from...

Copyright © 2020 scienceboard.net

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter